.
.
.
.
The chart below identifies FDA May 2014 Products Receiving Orphan Designation as of 05/31/14 in ascending “Orphan Drug Designation Date” order.
FDA May 2014 Products Receiving Orphan Designation
| # | Generic Name/ODD Date | Sponsor Company | Indication |
| 1 | Filanesib/ 05.06 | Array BioPharma | Multiple Myeloma |
| 2 | Autologous dendritic cells pulsed with allogeneic tumor cell lysate/ 05.06 | Amphera BV (Netherlands) | Malignant Mesothelioma |
| 3 | Ex vivo cultured human mesenchymal stromal cells / 05.08 | iCell Science AB (Sweden) | Prevention of graft rejection following solid organ transplantation |
| 4 | Adalimumab/ 05.13 | AbbVie | Uveitis |
| 5 | Diazoxide choline / 05.13 | Essentialis | Prader-Willi Syndrome |
| 6 | Vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein / 05.13 | PhaseBio Pharmaceuticals | Pulmonary arterial hypertension |
| 7 | (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide / 05.14 | Karyopharm Therapeutics | Diffuse large B-cell lymphoma |
| 8 | 177Lu-tetraxetan-tetulomab / 05.14 | Nordic Nanovector AS (Norway) | Follicular Lymphoma |
| 9 | Selinexor; (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N-(pyrazin-2-yl)acrylohydrazide / 05.14 | Karyopharm Therapeutics | Acute myeloid leukemia |
| 10 | Menadione Sodium Bisulfite/ 05.14 |
View original 198 more words
Filed under: Uncategorized
